查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576811

非專利藥市場：按藥物類別、治療類型、癌症類型、給藥途徑、最終用戶分類 - 2025-2030 年全球預測

Generic Oncology Drugs Market by Drug Class, Therapy Type, Cancer Type, Route Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年非專利藥市值為359.4億美元，預計2024年將達到387.4億美元，複合年成長率為7.06%，到2030年將達到579.7億美元。

非專利藥市場範圍包括用於癌症治療的非品牌藥物的開拓、生產和分銷。這些藥物為品牌藥物提供了具有成本效益的替代品，並促進更廣泛地獲得癌症治療。癌症發生率和醫療費用的增加凸顯了對非專利抗癌藥物的需求，因此需要負擔得起且有效的治療解決方案。治療涵蓋多種癌症類型，最終用戶主要是醫院、診所和癌症治療中心。關鍵的成長要素包括癌症發病率上升、重磅抗癌藥物的專利到期以及政府鼓勵使用學名藥的支持措施。藥品製造的持續進步和法規環境的改善進一步支持了市場擴張。然而，它們面臨著嚴格的監管要求、潛在的生物等效性問題以及可能影響利潤率的品牌藥物的激烈競爭等限制。鼓勵製藥公司專注於先進的藥物輸送機制、具有成本效益的開發流程和改進配方等創新，以保持競爭優勢。此外，您可以透過開拓醫療保健需求不斷成長的新興市場來發現潛在的商機。投資於提高藥物療效、減少副作用和個人化醫療方法的研究可以開闢新的成長途徑。儘管面臨挑戰，但在醫療改革、醫療保健意識不斷提高以及對降低醫療成本的日益關注的推動下，非專利藥市場仍提供了巨大的機會。提高供應鏈效率、投資策略夥伴關係以及培養強大的開發平臺的公司很可能會成功。了解市場動態，例如區域需求差異和患者偏好，可以深入了解滿足市場需求的策略定位和創新。透過解決限制並利用成長機會，公司可以對腫瘤學領域產生重大影響，同時加快獲得基本癌症治療的機會。

主要市場統計
基準年[2023] 359.4億美元
預測年份 [2024] 387.4億美元
預測年份 [2030] 579.7億美元
複合年成長率（%） 7.06%

市場動態：揭示快速發展的非專利藥市場的關鍵市場洞察

供需的動態交互作用正在改變非專利抗癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於全球癌症發生率上升，對非專利抗癌藥物的需求增加
    • 政府對非專利藥抗癌藥物研發的措施和資助
    • 不斷上漲的醫療成本促使人們轉向更具成本效益的學名藥
    • 由於越來越多的重磅抗癌藥物專利到期，向學名藥的轉變正在取得進展。
  • 市場限制因素
    • 嚴格的專利法和智慧財產權問題阻礙學名藥進入
    • 供應鏈脆弱性和原料短缺影響學名藥生產
  • 市場機會
    • 透過創新技術改變非專利藥市場並改善治療效果
    • 透過策略夥伴關係和聯盟加強學名藥研發
    • 監管發展和加速核准途徑推動非專利腫瘤學的成長
  • 市場挑戰
    • 品牌藥的競爭和影響非專利藥市場的智慧財產權問題
    • 由於患者認知度低以及對非專利抗癌藥物有效性的不信任，市場滲透率下降

波特五力：駕馭非專利藥市場的策略工具

波特的五力框架是了解非專利藥市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解非專利藥市場的外部影響

外部宏觀環境因素在塑造非專利藥市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解非專利藥市場的競爭狀況

對非專利藥市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 在非專利藥市場中的定位矩陣供應商績效評估

FPNV定位矩陣是評估非專利藥市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，非專利藥市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對非專利癌症藥物市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著全球癌症發生率的增加，對非專利藥的需求也隨之增加
      • 政府措施和增加對非專利抗癌藥物研發的資助
      • 不斷上漲的醫療保健成本推動轉向具有成本效益的非專利腫瘤學解決方案
      • 主要抗癌藥物的專利到期不斷增加，為轉向學名藥平了道路
    • 抑制因素
      • 嚴格的專利法和智慧財產權挑戰阻礙非專利藥的進入
      • 供應鏈脆弱性和原料短缺影響非專利藥生產
    • 機會
      • 創新技術改變非專利藥市場並改善治療效果
      • 策略夥伴關係與合作，加強非專利藥的研發
      • 監管進步和加速核准流程推動非專利腫瘤學的成長
    • 任務
      • 品牌藥的競爭和智慧財產權問題正在推動非專利藥市場的發展
      • 由於患者認知度低以及對非專利抗癌藥物有效性的不信任，市場滲透緩慢。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物非專利分類的學名藥市場

  • 烷化劑
    • 含鉑類藥物
  • 單株抗體
    • 抗CD20
    • 抗CD30
    • 抗HER2
  • 蛋白酪氨酸激酶抑制劑
    • BCR-ABL抑制劑
    • EGFR抑制劑

第7章按治療類型分類的非專利藥市場

  • 輔助性治療
  • 同步放射線治療
  • 新輔助輔助性治療
  • 姑息化療

第8章按癌症類型非專利藥市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
    • 非小細胞肺癌
    • 小細胞肺癌
  • 攝護腺癌

第9章非專利藥市場：依給藥途徑

  • 可注射的
  • 口服
  • 話題

第 10 章非專利藥市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 腫瘤門診

第11章美洲非專利藥癌症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區非專利藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的非專利藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0038

The Generic Oncology Drugs Market was valued at USD 35.94 billion in 2023, expected to reach USD 38.74 billion in 2024, and is projected to grow at a CAGR of 7.06%, to USD 57.97 billion by 2030.

The scope of the generic oncology drugs market encompasses the development, production, and distribution of non-branded medications used for cancer treatment. These drugs offer cost-effective alternatives to branded medications, facilitating broader access to cancer therapies. The necessity for generic oncology drugs is emphasized by the increasing cancer prevalence and healthcare costs, necessitating affordable and effective treatment solutions. Applications span across various cancer types, with end-users primarily including hospitals, clinics, and cancer treatment centers. Key growth influencers include rising cancer incidences, patent expirations of blockbuster oncology drugs, and supportive government initiatives promoting generic drug use. Ongoing advancements in pharmaceutical manufacturing and supportive regulatory environments further bolster market expansion. However, the market faces limitations like stringent regulatory requirements, potential concerns about bioequivalence, and stiff competition from branded drugs, which may affect profit margins. Pharmaceutical companies are recommended to focus on innovations such as advanced drug delivery mechanisms, cost-effective development processes, and enhanced drug formulations to maintain competitive advantage. Additionally, exploring emerging markets with rising healthcare needs can uncover potential opportunities. Investing in research to improve drug efficacy, reduce side effects, and tailor personalized medicine approaches can open new avenues for growth. Despite its challenges, the generic oncology drugs market offers substantial opportunities driven by healthcare reforms, increasing healthcare awareness, and a growing emphasis on reducing medical expenses. Companies that enhance their supply chain efficiency, invest in strategic partnerships, and foster robust research and development pipelines will likely thrive. Understanding market dynamics, including regional demand variations and patient preferences, can provide insights into strategic positioning and innovation tailored to market needs. By addressing limitations and capitalizing on growth opportunities, businesses can significantly impact the oncology landscape while promoting wider access to essential cancer treatment therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 35.94 billion
Estimated Year [2024] USD 38.74 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 7.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Oncology Drugs Market

The Generic Oncology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer globally increasing the demand for generic oncology drugs
    • Government initiatives and funding boost for generic cancer drug research and development
    • Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
    • Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
  • Market Restraints
    • Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
    • Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
  • Market Opportunities
    • Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
    • Strategic partnerships and collaborations enhancing research and development in generic oncology medications
    • Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
  • Market Challenges
    • Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
    • Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake

Porter's Five Forces: A Strategic Tool for Navigating the Generic Oncology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Oncology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Oncology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Oncology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Oncology Drugs Market

A detailed market share analysis in the Generic Oncology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Oncology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Oncology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Oncology Drugs Market

A strategic analysis of the Generic Oncology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Generic Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Alkylating Agents, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors. The Alkylating Agents is further studied across Platinum-Based Drugs. The Monoclonal Antibodies is further studied across Anti-CD20, Anti-CD30, and Anti-HER2. The Tyrosine Kinase Inhibitors is further studied across BCR-ABL Inhibitors and EGFR Inhibitors.
  • Based on Therapy Type, market is studied across Adjuvant Therapy, Concurrent Chemoradiation Therapy, Neoadjuvant Therapy, and Palliative Chemotherapy.
  • Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer. The Lung Cancer is further studied across Non-Small Cell Lung Cancer and Small Cell Lung Cancer.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Oncology Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally increasing the demand for generic oncology drugs
      • 5.1.1.2. Government initiatives and funding boost for generic cancer drug research and development
      • 5.1.1.3. Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
      • 5.1.1.4. Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
      • 5.1.2.2. Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
      • 5.1.3.2. Strategic partnerships and collaborations enhancing research and development in generic oncology medications
      • 5.1.3.3. Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
      • 5.1.4.2. Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Oncology Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Alkylating Agents
    • 6.2.1. Platinum-Based Drugs
  • 6.3. Monoclonal Antibodies
    • 6.3.1. Anti-CD20
    • 6.3.2. Anti-CD30
    • 6.3.3. Anti-HER2
  • 6.4. Tyrosine Kinase Inhibitors
    • 6.4.1. BCR-ABL Inhibitors
    • 6.4.2. EGFR Inhibitors

7. Generic Oncology Drugs Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Concurrent Chemoradiation Therapy
  • 7.4. Neoadjuvant Therapy
  • 7.5. Palliative Chemotherapy

8. Generic Oncology Drugs Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
    • 8.4.1. Non-Small Cell Lung Cancer
    • 8.4.2. Small Cell Lung Cancer
  • 8.5. Prostate Cancer

9. Generic Oncology Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Generic Oncology Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Oncology Clinics

11. Americas Generic Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Generic Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Generic Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eli Lilly and Company
  • 9. Fresenius Kabi AG
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GENERIC ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC ONCOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PLATINUM-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD30, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CONCURRENT CHEMORADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PALLIATIVE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR GENERIC ONCO